预约演示

更新于：2025-05-07

Xerosis

干燥症

更新于：2025-05-07

基本信息

别名

XEROSIS、Xerosis、xerosis

+ [2]

简介

Abnormal body tissue dryness.

关联

项与干燥症相关的药物

Lactobarriome 5% Cream

靶点-

作用机制-

在研机构

Soon Chun Hyang University

原研机构

Soon Chun Hyang University

在研适应症

瘙痒 [+1]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

ADE-G1

靶点-

作用机制-

在研机构

University of Nantes

原研机构

University of Nantes

在研适应症

干燥症

非在研适应症-

最高研发阶段临床阶段不明

首次获批国家/地区-

首次获批日期1800-01-20

SM2866

靶点-

作用机制-

在研机构

北京烁星生物医药科技有限公司

原研机构

北京烁星生物医药科技有限公司

在研适应症

干燥症 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与干燥症相关的临床试验

ACTRN12624001057572

/ Not yet recruitingN/AIIT

Alterations in skin hydration, moisture and genomic in adult patients with dry skin conditions following daily oral palm tocotrienol and squalene (STGAIATM) supplementation

开始日期2024-11-04

申办/合作机构

Monash University Malaysia Sdn. Bhd.

[+1]

NCT06706050

/ Completed临床1/2期IIT

Clinical Evaluation of Lactobarriome 5% Cream's Efficacy on Dry Skin for Improving Skin Hydration and Transepidermal Water Loss, Relieving Pruritus, and Altering the Skin Microbiome

The purpose of this clinical trial is to assess the skin hydration and transepidermal water loss improvement, pruritus relief, and microbiome alteration effects of a Lactobacillus sp. product (Lactobarriome 5% cream) compared to a placebo cream to prove the skin improvement effects of Lactobarriome 5%, which is a nature-friendly material derived from intravaginal microflora that can replace chemical components commonly used as ingredients for existing cosmetics.
The impact of Lactobarriome 5% cream, formulated with LP51 culture filtrate, on dry skin was assessed through a 4-week double-blind clinical trial. Participants were selected based on predefined inclusion and exclusion criteria. Using a simple randomization method, participants were assigned to either the experimental group (receiving the test formulation) or the control group (receiving a placebo). The products were applied twice daily-morning and evening-to a 3 cm area on both the proximal and distal sides of the designated arm's crook. Clinical evaluations were conducted at baseline, as well as after 2 weeks and 4 weeks of product use. These assessments included visual inspections, subjective pruritus evaluations, skin hydration levels, and transepidermal water loss (TEWL) measurements, all performed by a skincare professional. Furthermore, magnified images were captured using a Folliscope, and skin samples were collected to analyze microbial changes post-treatment. Before application, the designated arm was washed with water and allowed to rest for 30 minutes under controlled conditions (22±2°C, 50±10% relative humidity).

开始日期2023-05-08

申办/合作机构

Soon Chun Hyang University

[+2]

ChiCTR2100052190

/ Suspended早期临床1期IIT

Clinical observation of siwu decoction in the treatment of xerosis pruritus

开始日期2022-03-01

申办/合作机构-

100 项与干燥症相关的临床结果

登录后查看更多信息

100 项与干燥症相关的转化医学

登录后查看更多信息

0 项与干燥症相关的专利（医药）

登录后查看更多信息

1,344

项与干燥症相关的文献（医药）

2025-12-31·Journal of Dermatological Treatment

Improving the quality of life of patients with inflammatory skin diseases: a multicenter evaluation of a ceramide-containing regimen in patients with atopic dermatitis, psoriasis and xerosis

Article

作者: Abbad-Jaime de Aragon, Carlota ; Berna-Rico, Emilio ; Gonzalez-Cantero, Álvaro ; Prieto, Leonor ; Abarquero-Cerezo, Mercedes

PURPOSEAtopic dermatitis (AD), psoriasis and xerosis are characterized by alterations in the skin barrier leading to symptoms that severely impair patients' quality of life (QoL). This multicenter, prospective study evaluated the benefits of a 4-week ceramide-containing regimen on the symptoms and QoL of patients with AD, psoriasis, or xerosis.MATERIALS AND METHODSClinical assessments (SCORAD, PASI, VAS), QoL and adherence to the treatment were evaluated at baseline and after 4 weeks.RESULTSA total of 312 patients (109 AD, 97 psoriasis and 106 xerosis) participated in the study; 59.3% female, mean age 42.4 years, no family history of AD, psoriasis or xerosis in ∼70% of patients. Significant clinical improvements after 4 weeks were reported: 61.2% reduction in SCORAD in AD; 65.5% reduction in PASI in psoriasis; and reductions in VAS for dryness, erythema and other symptoms in xerosis patients. QoL improved in all groups (67.2% AD, 64.7% psoriasis, 77.3% xerosis), with a significant proportion of patients reducing their concomitant treatments. Most patients adhered to the regimen, and no adverse reactions were reported.CONCLUSIONSA ceramide-containing regimen reduced the symptoms commonly associated with AD, psoriasis, and xerosis and improves patients' QoL. Limitations include the lack of control group and limiting conclusions about ceramides' contribution on effectiveness.

2025-05-01·Journal of Pediatric Hematology/Oncology

Dupilumab for Atopic Dermatitis-like Chronic Graft-versus-Host Disease in Three Pediatric Hematopoietic Cell Transplant Recipients

Article

作者: Jones, Margaret M. ; Connelly, James A. ; Ishee, Savannah L. ; Jenkins, Meredith M.

Atopic dermatitis (AD)-like graft-versus-host disease (GVHD) is a chronic form of skin GVHD with features that include erythema, xerosis, scaling, and pruritus. Patients often require treatment with systemic immunosuppression and aggressive topical therapies for relief. Long-term effects of chronic immunosuppression are undesirable and alternative therapies are needed. A retrospective review of 3 patients receiving dupilumab (DUP) for AD-like cGVHD was conducted. Data collected included demographics, transplant history, and GVHD management and outcomes. Information relating to DUP included dose, route, frequency, and safety based on dermatologic reactions, ocular toxicities, and infections. Patients had differing underlying conditions, transplant types, cell sources, and GVHD prophylactic therapies. Three patients received tacrolimus and topical corticosteroids for GVHD treatment, and 1 also received sirolimus and ruxolitinib. After the initial DUP dose, all patients experienced improvement in their GVHD. To date, all patients have complete remission of their skin cGVHD and have weaned off other therapies. No patients experienced dermatologic or ocular toxicities, and no infections were reported. DUP was efficacious and safe for treating AD-like cGVHD in our 3 pediatric patients. Further investigations are warranted to determine the appropriate placement in therapy.

2025-04-01·Journal of Drugs in Dermatology

Top Chief Complaints and Diagnoses for Outpatient Dermatology Patients of Color

Article

作者: Atwal, Sanmeet ; Elbuluk, Nada ; Blair, Kayla ; N. Montgomery, Simone ; Carolina Mora Hurtado, Arielle ; Gonzalez, Melissa ; L. Saizan, Autumn ; Rodriguez, Ivan ; C. Syder, Nicole ; Rodman, Jack ; Gonzalez, Sarah ; Hao, Audrey

BACKGROUNDBy 2044, people with skin of color (SOC) in the United States are projected to become the majority of the population, yet research and practice gaps remain regarding the dermatologic conditions most common and concerning to populations with SOC.1,2 Objective: To investigate the most common outpatient dermatologic chief complaints and diagnoses in patients with SOC.METHODSA retrospective chart review was conducted investigating the top chief complaints and diagnoses in children and adult patients with SOC seen at the University of Southern California outpatient dermatology clinics over 10 years, from 2009 to 2019.RESULTSA total of 4572 individuals were identified (2326 [58.9%] female; mean age [SD]: 46.0 [19.9] years). The 5 most common skin concerns were skin examination (21.5%), bumps/growths (20.8%), rash (19.8%), acne (10.0%), and skin discoloration (8.5%). The 5 most common diagnoses were benign nevi/neoplasm (38.8%), followed by dermatitis (20.8%), acne (13.3%), eczema and/or xerosis (9.0%), and dyspigmentation (7.7%). Differences were observed across racial/ethnic, age, and gender groups.CONCLUSIONFindings from this study contribute valuable insights regarding the potential motivations for seeking dermatologic care across various demographical groups, underscoring the importance of patient-centered, evidence-based, and culturally competent care in the diagnosis and treatment of dermatological disease across diverse populations. J Drugs Dermatol. 2025;24(4):403-409. doi:10.36849/JDD.8532R1.

项与干燥症相关的新闻（医药）

2025-04-30

·佰傲谷BioValley

一家自免公司正在关闭

最近，一家自身免疫性疾病生物技术公司正在关闭。Octagon Therapeutics的联合创始人兼首席执行Isaac Stoner，在LinkedIn上披露了Octagon公司关闭的决定。根据报道，这一决定是基于Octagon一个领先的B细胞免疫调节剂项目被取消优先级，以及高潜力管线未解决的生物学问题之后做出的。关键技术出问题了Octagon Therapeutics是一家私营的生物技术公司，最初专注于开发针对多种耐药性感染的抗生素，后来转向自身免疫性疾病和炎症性疾病的药物开发。Octagon使用新颖的方式研究功能生物学，利用一系列临床样本和专有的发现平台，阐明糖生物学在免疫病理学发展中的独特作用。Octagon基于这种方法开发了多个项目，并吸引了诺和诺德的关注。2022年9月，Octagon与诺和诺德建立了以炎症为重点的研究联盟。Octagon最领先的管线是OCT50，OCT50旨在恢复Siglec-2的内源性作用，选择性抑制自身反应性B细胞并重置免疫功能，以治疗多种自免疾病，包括SLE/CLE、多发性硬化症、干燥症等。但在最新信息披露当中，Octagon取消了OCT50的优先级（原因未披露），提出了下一代核心管线OCT102。OCT102是一款炎症候选药物，靶标未公开，旨在抑制CD8+ T细胞分泌炎性因子，包括IL-6、IL-7和1型干扰素。但是在OCT102的目标概念验证阶段，Octagon遇到了未解决的生物学问题。领先的OCT50被没有原因的放弃，OCT102又遇到生物学问题，这很可能预示着Octagon的生物学发现平台出了问题——这是没有办法解决的，或许这才是Octagon毫无挣扎便宣布关闭的原因。小结Octagon在2022年吸引到了诺和诺德的青睐，在去年还完成了1100万美元的融资，都表明Octagon选择自免方向非常正确。但是，两款管线都没能走到临床阶段就出了问题，这对于一家私营公司是很致命的问题，尤其是现在生物制药困难的融资情况下。一是面临底层技术的错误，二是面临困难的融资现况，干脆关闭及时止损或许更好。参考资料：1.https://www.fiercebiotech.com/biotech/octagon-shuts-down-after-rd-challenges-put-it-behind-8-ball2.https://www.octagontherapeutics.com/science3.https://www.octagontherapeutics.com/pipeline4.https://www.prnewswire.com/news-releases/octagon-therapeutics-enters-inflammation-focused-research-alliance-with-novo-nordisk-301627501.html本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处········

临床研究

2025-04-08

·医药观澜

恒瑞医药JAK1抑制剂第三项适应症获批，治疗特应性皮炎

▎药明康德内容团队报道今日（4月8日），中国国家药品监督管理局（NMPA）官网公示显示，恒瑞医药递交SHR0302片（艾玛昔替尼）的新适应症上市申请已获得批准。公开资料显示，艾玛昔替尼是一款JAK1抑制剂，本次获批针对的适应症为：用于对局部外用治疗或其他系统性治疗应答不充分或不耐受的成人和12岁及以上青少年中度至重度特应性皮炎患者。这也是该产品在中国获批的第三项适应症。截图来源：NMPA官网特应性皮炎是一种慢性炎症性皮肤病，病变复杂，临床表现和症状多样，典型的表现为皮肤色素沉着、干燥、龟裂或鳞状的斑块、皮肤瘙痒——尤其是夜间瘙痒，严重影响患者的生活质量。这些患者面对的是病程漫长的折磨，以及临床缺少长期有效控制疾病疗法的现状，研发适合口服的、更安全有效的治疗药物需求十分迫切。艾玛昔替尼是一种高选择性的JAK1抑制剂，对JAK1的选择性是对JAK2的16倍。该药物能通过高选择性抑制JAK1，调节IL-4、IL-5、IL-13、IFN-γ和其他参与AD发病机制的细胞因子的信号传导。因其对JAK2的抑制性极低，也能尽量降低发生中性粒细胞减少症与贫血的风险。2025年3月21日，硫酸艾玛昔替尼片在中国获批上市，用于对一种或多种TNF抑制剂疗效不佳或不耐受的活动性强直性脊柱炎成人患者；3月31日，该药获NMPA批准用于治疗成人中重度活动性类风湿关节炎患者。2024年3月，恒瑞医药宣布在第82届美国皮肤病学会年会（AAD）介绍了艾玛昔替尼治疗中重度特应性皮炎（AD）的3期研究结果。该研究在最新突破性进展（Late-Breaking Research）专场发表口头报告。这项3期临研究纳入了来自中国与加拿大的53个医学中心的336例中重度AD患者。研究的共同主要终点为16周时实现研究者总体评估（IGA）应答与湿疹面积和严重度指数改善75％（EASI-75）的患者比例，长期终点包括52周治疗期内实现IGA应答与EASI-75应答的患者比例、实现最严重瘙痒强度数值评定量表（WI-NRS）应答（WI-NRS改善≥4分）的患者比例与整个治疗期间内的药物安全性与耐受性。结果显示，艾玛昔替尼治疗青少年与成人中重度AD患者，对疾病活动度与瘙痒症状的改善显著优于安慰剂，且安全性与耐受性良好。16周时，艾玛昔替尼4mg组、8mg组与安慰剂组的IGA应答率分别为36.3％、42.0％、9.0％，表明该药物能有效改善中重度AD的疾病活动度。在改善皮损方面，艾玛昔替尼也展示了显著的疗效。16周时艾玛昔替尼4mg组、8mg组与安慰剂组的EASI-75应答率分别为54.0％、66.1％、21.6％。艾玛昔替尼还能显著改善受试者的瘙痒症状。16周时，艾玛昔替尼4mg组、8mg组、安慰剂组的WI-NRS应答率分别为37.2％、40.2％与12.6％。完成16周的治疗阶段后，共有300例患者进入扩展阶段。最终，258例患者完成了52周的治疗。结果显示：从基线开始持续使用艾玛昔替尼治疗的患者中，第16周到第52周的治疗期内，IGA与EASI-75的应答率仍能长期维持，52周时，艾玛昔替尼4mg组与8mg组的IGA应答率分别为42.3％与40.2％；EASI-75应答率分别为60.6％与55.9％。在瘙痒方面，从基线开始持续使用艾玛昔替尼治疗的患者中，从第16周到第52周的治疗期内，WI-NRS应答率同样维持稳定。52周时，艾玛昔替尼4mg组与8mg组的WI-NRS应答率分别为59.6％与45.1％。在从基线开始持续使用艾玛昔替尼治疗的患者中，早在第1次评估时，就观察到了多个患者报告结局（PRO）的显著改善，第16周至第52周的治疗期内疗效持续。在52周的治疗期间内，艾玛昔替尼4mg组与8mg组不良事件发生率基本相当，且多为轻度，因不良反应导致的停药较少，未报告恶性肿瘤、主要心血管事件（MACE）或血栓栓塞事件，未出现新的安全信号。研究者认为，该3期临床研究表明，中重度AD患者使用艾玛昔替尼治疗16周，皮损与瘙痒症状均得到了显著改善，52周的长期随访也证实，药物疗效长期持续，且整体安全性良好。参考资料：[1]2025年03月31日药品批准证明文件送达信息. From https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250331143424124.html[2]恒瑞医药关于药物上市许可申请获受理的提示性公告. Retrieved Nov 8，2023，from http://www.cninfo.com.cn/new/disclosure/detail?stockCode=600276&announcementId=1218273609&orgId=gssh0600276&announcementTime=2023-11-08[3]2024 AAD︱恒瑞自免1类创新药艾玛昔替尼治疗中重度特应性皮炎Ⅲ期研究亮相口头报告告. Retrieved Mar 11，2024，from https://mp.weixin.qq.com/s/mKR_4e-cYAiwSdXs3p-pvA本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期临床结果上市批准临床成功

2025-02-16

·恒瑞医药

国产JAK1抑制剂艾玛昔替尼软膏特应性皮炎适应症上市申报获受理

近日，JAK1抑制剂艾玛昔替尼软膏（SHR0302碱软膏）的药品上市许可申请获国家药监局受理，本品适用于成人轻度至中度特应性皮炎的局部外用治疗。目前尚未有国内企业自研的JAK1抑制剂外用制剂获批上市。 01 关于艾玛昔替尼软膏III期临床试验 2024年9月，艾玛昔替尼软膏III期临床试验达到了方案预设的共同主要研究终点。该研究是一项在成人轻度至中度特应性皮炎患者中评价艾玛昔替尼软膏局部治疗的有效性和安全性的随机、双盲和赋形剂对照II/III期研究，由复旦大学附属华山医院徐金华教授担任主要研究者，Ⅲ期研究部分共入组367例成人轻度至中度特应性皮炎患者。艾玛昔替尼软膏组在共同主要终点上显著优于赋形剂组，且在成人特应性皮炎患者中长期治疗的安全性、耐受性良好，与其他JAK1抑制剂相比未发现新的安全性信号1。 02 关于特应性皮炎特应性皮炎是一种慢性炎症性皮肤病，病变复杂，临床表现和症状多样，典型的表现为皮肤色素沉着、干燥、龟裂或鳞状的斑块、皮肤瘙痒，严重影响患者的生活质量，临床缺少长期有效控制疾病的治疗手段。在全球大部分国家，特应性皮炎的成人患病率达8-10%2；特应性皮炎已经成为与糖尿病、癫痫等慢性疾病具有相似疾病负担的全球性健康问题。目前国际上积极研究针对调节免疫反应的新产品，研发更安全有效的治疗药物需求十分迫切。 03 关于艾玛昔替尼艾玛昔替尼是我国自主研发的高选择性的JAK1抑制剂，国家1类新药，可通过抑制JAK1信号传导发挥抗炎和抑制免疫的生物学效应，目前口服片剂和外用软膏两种剂型正在进行多种适应症的临床开发，且绝大多数适应症的临床研究已进入III期临床试验，其中硫酸艾玛昔替尼片强直性脊柱炎、特应性皮炎、类风湿关节炎和斑秃4项适应症的上市申请均已获得国家药监局受理。2018年，公司将JAK1抑制剂硫酸艾玛昔替尼（SHR0302）许可给美国Arcutis公司，让创新药品惠及全球患者。参考文献： 1. 根据研究资料整理. 2. Ständer S. Atopic Dermatitis. N Engl J Med. 2021 Mar 25;384(12):1136-1143. DOI: 10.1056/NEJMra2023911. PMID: 33761208. 声明： 1. 本新闻旨在发布研发注册进展信息，仅供医疗卫生专业人士参阅，非广告用途。 2. 恒瑞医药不推荐任何未被批准的药品、适应症的使用。撰稿：王慧郜振彦排版：程梦真责编：王玲往期精选 | 研发创新 | 全球首个超长效PCSK9单抗！恒瑞降脂创新药瑞卡西单抗获批上市慢病创新里程碑！恒瑞首个自免创新药夫那奇珠单抗获批上市 | 国际化 | 海外BD再下一城！恒瑞医药DLL3 ADC创新药SHR-4849实现海外独家许可海外BD再传捷报！恒瑞医药GLP-1类创新药组合实现海外许可 | 重磅奖项 | 喜报！恒瑞医药荣获2023年度国家科技进步奖恒瑞医药连续六年入选全球制药企业50强榜单！ | 社会公益 | “健康中国行·重走长征路”项目启动仪式圆满举行！恒瑞提供公益支持，助力健康中国恒瑞医药集团向中国扶贫基金会捐赠3000万设立“健康帮扶基金”

上市批准临床3期申请上市